pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Komzifti
drug · small molecule
save

ziftomenib

Marketedupdated 3mo ago
by $KURA Kura Oncology, Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval4 co-mentions · 1 sources
  • tagSmall Molecule2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Phase 1 2 (across all indications), with 2 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying ziftomenib

  • phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLrecruitingn=1,300
  • phase2First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemiarecruitingn=263
  • phase2TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIrecruitingn=90
  • phase1Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemiarecruitingn=171
  • phase1A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLrecruitingn=420
  • phase2Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapynot yet recruitingn=70
  • phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)recruitingn=157
  • phase1A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemiasrecruitingn=22
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Nov 13, 2030
~4.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Jul 16, 2044compositionUS 12410184
  • Jul 16, 2044formulationUS 12521396
  • Sep 6, 2038method-of-use (U-4349)US 11944627
  • Mar 15, 2037compositionUS 10781218
  • Mar 15, 2037method-of-use (U-4351)US 11673898
  • Jan 26, 2037method-of-use (U-4353)US 10869868
  • Mar 16, 2036compositionUS 10077271
  • Mar 16, 2036method-of-use (U-4354)US 10174041

FDA exclusivities (1)

  • Nov 13, 2030NCENew Chemical Entity (5y)4.2y

News(0)

no news has mentioned this drug yet

brand
Komzifti
generic
ziftomenib
indication
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?